CN110996928A - 吉卡宾、其药学上可接受的盐、其组合物和其使用方法 - Google Patents

吉卡宾、其药学上可接受的盐、其组合物和其使用方法 Download PDF

Info

Publication number
CN110996928A
CN110996928A CN201880040555.5A CN201880040555A CN110996928A CN 110996928 A CN110996928 A CN 110996928A CN 201880040555 A CN201880040555 A CN 201880040555A CN 110996928 A CN110996928 A CN 110996928A
Authority
CN
China
Prior art keywords
gemcabene
subject
pharmaceutically acceptable
present
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880040555.5A
Other languages
English (en)
Chinese (zh)
Inventor
D.C.安尼丘
C.L.比斯盖尔
J.R.戈麦斯
S.赫克霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yao Shi Treatment Co
Original Assignee
Yao Shi Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yao Shi Treatment Co filed Critical Yao Shi Treatment Co
Publication of CN110996928A publication Critical patent/CN110996928A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201880040555.5A 2017-04-18 2018-04-18 吉卡宾、其药学上可接受的盐、其组合物和其使用方法 Pending CN110996928A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762486728P 2017-04-18 2017-04-18
US201762486822P 2017-04-18 2017-04-18
US62/486822 2017-04-18
US62/486728 2017-04-18
US201762569358P 2017-10-06 2017-10-06
US62/569358 2017-10-06
US201762584576P 2017-11-10 2017-11-10
US62/584576 2017-11-10
PCT/US2018/028113 WO2018195163A1 (en) 2017-04-18 2018-04-18 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Publications (1)

Publication Number Publication Date
CN110996928A true CN110996928A (zh) 2020-04-10

Family

ID=63791570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040555.5A Pending CN110996928A (zh) 2017-04-18 2018-04-18 吉卡宾、其药学上可接受的盐、其组合物和其使用方法

Country Status (9)

Country Link
US (4) US20180297929A1 (cg-RX-API-DMAC7.html)
EP (1) EP3612171A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020516622A (cg-RX-API-DMAC7.html)
KR (1) KR20200054910A (cg-RX-API-DMAC7.html)
CN (1) CN110996928A (cg-RX-API-DMAC7.html)
CA (1) CA3059073A1 (cg-RX-API-DMAC7.html)
IL (1) IL269884B2 (cg-RX-API-DMAC7.html)
TW (1) TW201902471A (cg-RX-API-DMAC7.html)
WO (1) WO2018195163A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
JP2022505033A (ja) * 2018-10-18 2022-01-14 ジェムフィアー セラピューティクス インコーポレイテッド ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
US20240226049A1 (en) * 2023-01-09 2024-07-11 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid
WO2024151311A1 (en) * 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
CN1182415A (zh) * 1995-03-24 1998-05-20 沃尼尔·朗伯公司 含有末端羧酸基或四唑基的二烃基醚
US6861555B2 (en) * 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20140154313A1 (en) * 2011-06-08 2014-06-05 Sti Pharma, Llc Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration
US20160137584A1 (en) * 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2033909A (en) 1934-12-19 1936-03-17 Niacet Chemicals Corp Manufacture of calcium levulinate
US4691034A (en) 1986-04-14 1987-09-01 Texaco, Inc. Purification of propylene oxide by treatment with calcium hydroxide in glycerol or sugar water
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
EP1017390B1 (en) 1997-07-31 2007-04-18 Kos Life Sciences, Inc. Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
NZ519550A (en) 2000-01-25 2003-11-28 Warner Lambert Co Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
CN100376570C (zh) 2000-10-13 2008-03-26 希拉生物化学股份有限公司 改善胞间传输的二氧戊环类似物
HUP0400381A2 (hu) 2001-06-29 2004-09-28 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
US20040192771A1 (en) 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
DE10211289A1 (de) 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
WO2003088962A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
AU2003227691B2 (en) 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
JP2006501238A (ja) 2002-08-22 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 骨関節炎を治療する方法
WO2004045596A1 (en) 2002-11-15 2004-06-03 Warner-Lambert Company Llc Method of lowering crp and reducing systemic inflammation
ES2645930T3 (es) 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
WO2005002557A1 (en) 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2628666A1 (en) 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US7777071B2 (en) 2006-08-11 2010-08-17 Ssv Therapeutics, Inc. Production of carnitine conjugate intermediates
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
FI20080353A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
US9486446B2 (en) 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
CZ300047B6 (cs) 2007-03-02 2009-01-21 Zentiva, A. S. Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
WO2008124505A2 (en) 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20090036414A1 (en) 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2009048938A1 (en) 2007-10-08 2009-04-16 Keen Ingredients, Inc. Quinoa grain processing and products
BRPI0822026B8 (pt) 2008-01-10 2021-05-25 Evonik Roehm Gmbh preparação farmacêutica ou nutracêutica, comprimido, gelatina ou cápsula de hpmc, e uso de uma ou uma mistura de uma pluralidade de polímeros ou copolímeros
US20090226515A1 (en) 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
FR2928925B1 (fr) 2008-03-19 2011-01-07 Centre Nat Rech Scient Complexes de bore ou d'aluminium, et leurs utilisations.
EP2285352A2 (en) 2008-05-13 2011-02-23 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
RU2010151944A (ru) 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
RU2404767C1 (ru) 2009-08-11 2010-11-27 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
AU2011270719B2 (en) 2010-06-24 2015-09-24 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
PL2592081T3 (pl) 2010-07-06 2017-07-31 Ono Pharmaceutical Co., Ltd. Pochodna tetrahydrokarboliny
TW201304823A (zh) 2010-12-27 2013-02-01 Takeda Pharmaceutical 口腔內崩壞錠
ES2608177T3 (es) 2010-12-27 2017-04-06 Gemphire Therapeutics Inc. Gemcabeno y derivados para el tratamiento de la pancreatitis
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
RU2491070C2 (ru) 2011-10-11 2013-08-27 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний
EP2787986B1 (en) 2011-12-08 2017-10-18 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
EP2604256B1 (en) 2011-12-14 2016-04-13 Hexal AG Multi layer coatings
JP6295205B2 (ja) * 2012-01-06 2018-03-14 ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. 心血管疾患のリスクを低減する方法
CN104127391B (zh) 2014-08-05 2016-08-24 李宝齐 一种含有阿托伐他汀钙的固体药物组合物
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
CN105434391A (zh) 2016-01-18 2016-03-30 上海蓝心医药科技有限公司 阿托伐他汀钙肠溶片及其制备方法和应用
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
WO2018209257A1 (en) 2017-05-11 2018-11-15 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
CN1182415A (zh) * 1995-03-24 1998-05-20 沃尼尔·朗伯公司 含有末端羧酸基或四唑基的二烃基醚
US6861555B2 (en) * 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20140154313A1 (en) * 2011-06-08 2014-06-05 Sti Pharma, Llc Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration
US20160137584A1 (en) * 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

Also Published As

Publication number Publication date
JP2023057082A (ja) 2023-04-20
KR20200054910A (ko) 2020-05-20
IL269884B2 (en) 2023-09-01
JP2020516622A (ja) 2020-06-11
TW201902471A (zh) 2019-01-16
US20200148617A1 (en) 2020-05-14
US20180297929A1 (en) 2018-10-18
IL269884A (cg-RX-API-DMAC7.html) 2019-11-28
IL269884B1 (en) 2023-05-01
EP3612171A1 (en) 2020-02-26
EP3612171A4 (en) 2020-10-21
US20260209157A1 (en) 2026-07-23
US20220332672A1 (en) 2022-10-20
US12503422B2 (en) 2025-12-23
CA3059073A1 (en) 2018-10-25
WO2018195163A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
US12503422B2 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
TWI268778B (en) Benzamide derivative-containing pharmaceutical formulation having improved solubility and oral absorptivity
US8552041B2 (en) Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
KR20180073665A (ko) 심혈관 질환의 치료를 위한 젬카빈 조합
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
TW201216962A (en) Formulation for solubility enhancement of poorly soluble drugs
JPWO2017018473A1 (ja) 錠剤
JPH02268178A (ja) 3―ホルミルアミノ―7―メチルスルホニルアミノ―6―フェノキシ―4h―1―ベンゾピラン―4―オンまたはその塩を含有する抗炎症製剤
JP2021532113A (ja) 経口投与可能であり、放出を修飾した薬学的投薬形態
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
JP2024009815A (ja) アキシチニブを含有する医薬組成物
CN113396138A (zh) 吉卡宾、其药学上可接受的盐、其组合物和其使用方法
US20190008779A1 (en) Gemcabene compositions and methods of use thereof
CN110721187A (zh) 用于治疗或预防心血管疾病的胆固醇酯转移蛋白(cetp)抑制剂和含所述抑制剂的药物组合物
CN112469398A (zh) 可口服给药并具有缓释作用的药物剂型
WO2025168614A1 (en) Pharmaceutical compositions comprising azd0780
JP2007512287A5 (cg-RX-API-DMAC7.html)
HK40027589A (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
JP7370125B2 (ja) エルロチニブを有効成分とする医薬錠剤
TW202103697A (zh) 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑
FR3109089A1 (fr) Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
WO2012122707A1 (zh) 季铵盐类化合物、其制备方法、药物组合物及用途
HK40060377B (en) Pharmaceutical combination preparation comprising ezetimibe and losartan
TW200944537A (en) Formulations comprising a phosphoindole compound and one or more second active agents
HK40041640A (en) Pharmaceutical dosage form which can be administered orally and has modified release

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027589

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410